Two subtypes of equilibrative transporters, es (equilibrative inhibitor-sensitive) and ei (equilibrative inhibitor-insensitive), are responsible for the majority of nucleoside flux across mammalian cell membranes. Sequence analyses of the representative genes, ENT1 {equilibrative nucleoside transporter 1; also known as SLC29A1 [solute carrier family 29 (nucleoside transporters), member 1]} and ENT2 (SLC29A2), suggest that protein kinase CK2-mediated phosphorylation may be involved in the regulation of es-and ei-mediated nucleoside transport. We used human osteosarcoma cells transfected with catalytically active or inactive α and α subunits of CK2 to assess the effects of CK2 manipulation on nucleoside transport activity. Expression of inactive CK2α (decreased CK2α activity) increased the number of binding sites (∼ 1. 3 H]adenosine uptake. Quantitative PCR showed a transient decrease in the expression of both hENT1 (human ENT1) and hENT2 mRNAs within 4-12 h of induction of the inactive CK2α subunit, but both transcripts had returned to control levels by 24 h. These data suggest that inhibition of CK2α reduced ei activity by attenuation of hENT2 transcription, while the increase in es/hENT1 activity was mediated by post-translational action of CK2. The observed modification in es activity was probably due to a CK2α -mediated change in the phosphorylation state of the ENT1 protein, or an interacting protein, effecting an increase in the plasma membrane lifetime of the transport proteins.
INTRODUCTION
Specific transport proteins are required for the transfer of hydrophilic nucleosides across cell membranes. These transporters are critical for the scavenging of nucleosides by cells lacking de novo purine biosynthesis, and for regulation of adenosine concentrations in the vicinity of extracellular purinergic receptors [1, 2] . The cellular uptake of several chemotherapeutic drugs, such as cytosine arabinoside and gemcitabine, is also dependent on nucleoside transporters [3, 4] .
Both Na + -independent equilibrative (SLC29) and Na + -dependent concentrative (SLC28) nucleoside transport systems exist [5, 6] . The equilibrative transporters are expressed ubiquitously, and two subtypes can be distinguished by their differential sensitivities to inhibition by NBMPR (nitrobenzylthioinosine; nitrobenzylmercaptopurine riboside). The es (equilibrative inhibitorsensitive) type of transport activity is inhibited by NBMPR in the nanomolar range, while inhibition of the ei (equilibrative inhibitor-insensitive) subtype requires micromolar concentrations of NBMPR [1] . Genes encoding proteins with es and ei characteristics have been designated ENT1 {equilibrative nucleoside transporter 1; also known as SLC29A1 [solute carrier family 29 (nucleoside transporters), member 1} and ENT2 (SLC29A2) respectively. Both transporters have 11 transmembrane domains, with a large intracellular loop joining transmembrane domains 6 and 7 which contains sites for phosphorylation by protein kinase CK2 ('casein kinase II') [7, 8] . We [9] , and others [10] , have identified mouse ENT1 splice variants that differ in having either one or two consensus sites for phosphorylation by CK2. Preliminary data suggest that the variant with only one CK2 site has reduced transport functionality relative to the variant with both CK2 consensus sites (M. Stolk and J. R. Hammond, unpublished work). Only a single ENT1 isoform, containing both of the CK2 sites, has been identified, to date, in human cells [8] .
Protein kinase CK2 is a serine/threonine protein kinase that is found in nearly all compartments of mammalian cells [11] , and exists as a heterotetramer composed of two catalytic (α) subunits and two regulatory (β) subunits [12] . It appears to play an important role in the control of cell growth and proliferation [12, 13] , with increased CK2 activity being associated with rapidly growing cells. Nucleoside transporter expression by mammalian cells has also been directly correlated with growth rate [3, 11, [14] [15] [16] , and CK2-mediated phosphorylation may be a factor in this regulation.
Little is known about how nucleoside transporters are regulated. It has been shown that activators and inhibitors of protein kinase C and/or protein kinase A modulate the activity of equilibrative nucleoside transporters in a variety of cell types [17] [18] [19] [20] . Changes also occur in nucleoside uptake rates and transporter subtype expression upon cell differentiation [19, 21, 22] . However, the mechanisms underlying these changes have not been elucidated, and no work has been conducted on the role of CK2 in this regard.
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From a clinical perspective, understanding how cells regulate nucleoside transport activity/expression would aid in the development of protocols for reducing the toxicity to the host of nucleoside analogues used in cancer and antiviral therapies [23] . Moreover, coronary vasodilators such as dipyridamole and draflazine act by blocking the re-entry of adenosine into the cell via nucleoside transporters, thereby enhancing the cardioprotective actions of adenosine released under ischaemic conditions [2, 24] . Understanding how cells regulate the number of functioning nucleoside transporters would aid in the more efficacious application of these therapies.
The present study was undertaken to determine whether manipulation of CK2 catalytic activity in human osteosarcoma cells would affect the capacity of these cells to accumulate nucleosides via equilibrative nucleoside transporters. In the absence of well defined pharmacological modifiers of CK2 activity [12, 25] , we employed a model consisting of human osteosarcoma cells stably transfected with active or inactive α and α CK2 catalytic subunits under the control of a TET (tetracycline)-regulated promoter [26] . The number of es transporters was assessed using the es-specific probe 3 H 2 O (1 mCi/g) was purchased from DuPont Canada Inc. (Markham, Ontario, Canada). Dulbecco's modified Eagle's medium and culture grade PBS were from GIBCO/BRL (Burlington, Ontario, Canada). BGS (bovine growth serum) was from VWR International (Mississauga, Ontario, Canada). Penicillin G and streptomycin sulphate were from ICN (Montreal, Quebec, Canada). Nonradiolabelled formycin B, NBMPR, 2-chloroadenosine, NBTGR (nitrobenzylthioguanosine), trypsin/EDTA, TET and dipyridamole {2,6-bis-(diethanolamino) -4,8-dipiperidinopyrimido-[5,4-d] . Polyclonal antibodies to CK2α or CK2α have been described previously [26] . Goat anti-rabbit secondary antibody conjugated with horseradish peroxidase was purchased from Bio-Rad (Hercules, CA, U.S.A.), and silicone oil (550 Fluid) was from Dow-Corning Inc. (Baltimore, MD, U.S.A.).
Cell lines
U2-OS/UTA6 cells stably transfected with an inducible bidirectional plasmid expressing the CK2β regulatory subunit coordinately with a HA (haemagglutinin A)-tagged version of the inactive α (GV7.21), active α (RS2.31) or inactive α (GV13. 35) catalytic subunit of CK2 were generated as described previously [26] . Cells were cultured in T175 flasks in Dulbecco's modified Eagle's medium containing 10 % (v/v) BGS plus penicillin G (100 units/ml) and streptomycin sulphate (100 µg/ml) and maintained in a humidified atmosphere of 5 % CO 2 at 37
• C. Cells were split into parallel cultures and grown in the presence (TET +) or absence (TET −) of 1.5 µg/ml TET for the times specified in the Results section prior to harvesting for the assays described below. Induced expression of the HA-tagged CK2 catalytic subunits was confirmed in the TET − cells by immunoblotting with the appropriate CK2α subunit-specific antibody [26] , and by RT-PCR (reverse transcription-PCR) using primers specific for the HAtagged CK2 transcript (see Figure 1) Assays were conducted at room temperature (∼ 22
• C) in Na + -free buffer to ensure that uptake of [ 3 H]substrate was due solely to the operation of the Na + -independent equilibrative transporters (es or ei). In some cases, cells were depleted of ATP to reduce intracellular metabolism ('trapping') of the [ 3 H]nucleoside substrate as its nucleotide derivatives, by sequential incubation with rotenone (20 ng/ml; 15 min at 37
• C) and 2-deoxyglucose (2 mM; 10 min at 37
• C) [28] . Uptake was initiated by addition of cell suspension (∼ 1 × 10 6 cells) to [ 3 H]substrate (0.5 ml final volume) layered over a 200 µl cushion of silicone/mineral oil (21:4, v/v) in 1.5 ml microcentrifuge tubes. Assays were terminated after defined incubation times by centrifugation (12 000 g) of cells through the oil. The estimated time required to pellet the cells through the oil layer (2 s) was included in all reported incubation times. The supernatant and oil were removed, and the cell pellets were digested in 250 µl of 1 M NaOH overnight (∼ 16 h) at room temperature. The digest was analysed for 3 H content by standard liquid-scintillation counting techniques. Uptake 
Real-time PCR
To determine whether induction of the inactive α subunit of CK2 in GV7.21 cells led to a change in ENT1 or ENT2 gene expression, quantitative real-time PCR amplification of hENT1 (human ENT1), hENT2 and human β-actin was performed. Total RNA was isolated from GV7.21 cells (in the presence or absence of TET) using the GenElute TM Total RNA mini-prep kit (Sigma) and then treated with DNase. A first-strand DNA template was generated using the Superscript TM First Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, U.S.A.). The removal of genomic DNA from the preparations was confirmed by conducting traditional RT-PCR for hENT1 (see Table 1 for primers used) in the absence of reverse transcriptase. PCR primers were designed to achieve product sizes of 215 bp for hENT1, 172 bp for hENT2 and 235 bp for β-actin (see Table 1 ). A Roche LightCycler was used to perform real-time PCR in 25 µl microcapillary tubes (Roche Diagnostics Canada, Laval, PQ, Canada) using SYBR GreenTaq ReadyMix TM (Sigma) with 2 µl of cDNA template per reaction. This system allows amplification and detection of products in a single reaction tube. Reaction conditions included an initial activation step of 30 s at 95
• C, followed by 40 cycles of ramping at 20
• C/s to hold for 0 s at 95 • C, ramping at 20 • C/s to hold for 5 s at 54
• C (for ENT1/ENT2) or 58
• C (for β-actin), ramping at 5
• C/s to hold for 13 s at 72
• C, and ramping at 20 • C/s to hold for 1 s at 80
, with a single acquisition of data before the start of each cycle. Data were analysed with LightCycler Software version 3 (Idaho Tech, Salt Lake City, UT, U.S.A.). To optimize the amplification of ENT1 and ENT2, melting curve analysis was used to determine the T m (melting temperature) of specific products and primer dimers. The following conditions were used: ramping at 20
• C/s to hold for 0 s at 95
• C, ramping at 20 • C/s to hold for 10 s at 65
• C, and continuous acquisition of data while ramping at 0.1 • C/s until reaching 95
• C. An additional signal acquisition step, 2-3
• C below the T m , was added after the elongation phase of PCR to ensure signal acquisition from specific target products.
Standard curves for amplification of hENT1, hENT2 and human β-actin were constructed using different amounts of cDNA template derived from GV7.21 cells. The levels of ENT1 and ENT2 transcripts were then assessed using duplicate sets of cDNAs derived from three distinct lots of RNA isolated from GV7.21 cells grown in the presence or absence of TET for the times indicated in the Results section. The cycle number at which the fluorescence signal was significantly higher than baseline (the crossing point; Cp) was used to calculate the relative concentrations of ENT1, ENT2 and β-actin from their standard curves. These data were then normalized to β-actin to account for differences in reverse transcription efficiencies and the amount of template in each reaction mixture. The products from the reactions described above were also run on a 1 % (w/v) agarose gel, along with a DNA ladder (GeneRuler TM DNA ladder mix; Fermentas, Burlington, ON, Canada), to confirm that all products were of the correct length for the primers used (Table 1) .
Data analysis
Experiments were conducted at least four times in duplicate, and results are expressed as means + − S.E.M. Non-linear regression analyses were performed using GraphPad Prism 4. Statistical differences between data sets were defined using Student's t test for paired or unpaired data, as appropriate, with P < 0.05 considered significant (Graphpad Instat 3.05).
RESULTS
It has been shown previously that removal of TET from GV7.21 cell cultures (induction of inactive CK2α ) resulted in significant changes in cell proliferation, presumably through inhibition of endogenous CK2-mediated phosphorylation activity [26] . Thus the degree of cell confluence was controlled in the present study, such that cells cultured in either the presence or the absence of TET were harvested from flasks at 60-80 % confluence. The expression of the recombinant HA-tagged catalytic CK2 subunit RNA was confirmed by RT-PCR ( Figure 1A) , and Western blots confirmed the induction of the catalytically active or inactive CK2α protein when cells were grown in the absence of TET ( Figure 1B) . HA-tagged CK2α transcript was observed by RT-PCR within 2 h of removal of TET from the cell medium. A very small amount of HA-tagged transcript was consistently observed in GV7.21 cells grown in the presence of TET ( Figure 1A ), suggesting minor 'leakage' of the TET-OFF transcriptional control system. However, there was no detectable HA-tagged CK2α protein expressed under TET+ conditions ( Figure 1B) .
[ 3 H]NBMPR binding
Binding of the high-affinity es transporter probe [ 3 H]NBMPR [29, 30] was saturable, with non-specific binding comprising less than 15 % of total binding at the highest concentration used (Figure 2A) . GV7.21 and RS2.31 cells grown in the presence of TET RT-PCR was performed using a sense primer specific for the HA tag and an antisense primer to the CK2α sequence (see Table 1 ). The results shown are representative of those derived from three independent GV7.21 + − TET pairs. The level of GAPDH (glyceraldehyde-3-phosphate dehydrogenase) expression, determined for each template preparation, is shown for comparison. Samples were resolved on 1.2 % (w/v) agarose gels with DNA size markers shown in the right lane. The HA-CK2 PCR product was of the expected size (282 bp). (B) Whole-cell extracts containing equal amounts of protein were prepared from RS2.31 and GV7.21 cells (+ − TET) and analysed by immunoblotting with antibodies to CK2α as described previously [26] . Table 2 ). However, decreasing CK2-mediated phosphorylation by the induction of the kinase-dead α subunit in GV7. 21 Figure 2B ). Interestingly, relative to the TET+ condition, there was a slight, but statistically significant, decrease (10 + − 6 %) in [
3 H]NBMPR B max prior (2-4 h after TET washout) to the longer-term increase ( Figure 2B ). In contrast with that seen in the GV7. 21 (Table 2) to calculate the K i for each inhibitor using the Cheng-Prusoff relationship [31] . The most effective inhibitor tested was dilazep (K i = 0.17 + − 0.04 nM), followed by draflazine The uptake of a range of concentrations of 2-chloro[ 3 H]adenosine was then assessed using a 5 s incubation time (minimum attainable) in GV7.21 cells (+ − TET; Figure 5 ). Parallel assays were conducted in the absence and presence of 50 nM NBMPR or 14 µM dipyridamole/NBMPR to allow the calculation of total, es-and ei-mediated uptake of 2-chloro[ 3 H]adenosine. Induction of the inactive CK2α subunit resulted in no significant change in the K m of 2-chloro[ 3 H]adenosine for the es transporter (∼ 25 µM), but did increase the V max of uptake by 80 %, from 6.7 pmol/s per µl in control cells to 12.1 pmol/s per µl in the cells expressing catalytically inactive CK2α (Table 3 ). In parallel, the maximum rate of uptake of 2-chloro[ 3 H]adenosine by the ei system was reduced by 28 % upon inhibition of CK2 activity; there was also a significant increase in the affinity of 2-chloro[ 3 H]adenosine for the ei transporter upon induction of the inactive CK2α (Table 3, Figure 5 ). These changes resulted in a shift in the es/ei uptake ratio To confirm that the data obtained using 2-chloro[ 3 H]adenosine were not peculiar to the substrate used, we assessed the ability of NBMPR to inhibit the uptake of 10 µM [ 3 H]formycin B by both GV7.21 ( Figure 6A ) and RS2.31 ( Figure 6B ) cells grown in the presence or absence of TET for 48 h. Formycin B is well established as a poorly metabolized substrate for both the es and ei transporter subtypes [32] . NBMPR inhibition of [ 3 H]formycin B uptake in both GV7.21 and RS2.31 cells was biphasic, with approx. 50 % of the uptake being sensitive to sub-nanomolar concentrations of NBMPR, and the remainder inhibited by NBMPR only at concentrations in excess of 300 nM. Induction of inactive CK2α in GV7.21 cells resulted in a 2-fold increase in es-mediated (NBMPR-sensitive) uptake, from 5.6 + − 0.4 pmol/10 6 cells under baseline conditions to 11 + − 2 pmol/10 6 cells upon inhibition of CK2α activity. In contrast, induction of the active α subunit in RS2.31 cells had no effect on the relative amount of es transport activity.
Analysis of ENT1 and ENT2 expression by real-time PCR
The amplification plots (fluorescence against cycle number) derived for hENT1, hENT2 and β-actin are shown in Figure 7 (A). The cycle number at which the fluorescence signal was significantly different from baseline (the crossing point; Cp) was used to compute the relative concentrations of the target gene products from their standard curves. Melting curves for all products had a single peak, indicating a high degree of product specificity. The lowest T m was for hENT1 at 83
• C, followed by hENT2 at 87
• C and human β-actin at 88
• C ( Figure 7B ). The PCR products obtained using these primers were all of the expected size (Table 1, Figure 7C ). When normalized to β-actin, there was ∼ 3-fold more hENT1 than hENT2 mRNA present in these cells. 3 H]adenosine. Parallel assays were conducted in the absence (total influx) and presence of either 50 nM NBMPR (NBMPR-resistant influx) or 14 µM dipyridamole/NBMPR (non-mediated uptake). The total transporter-mediated uptake of substrate was calculated as the total influx minus the nonmediated component. The ei-mediated uptake was calculated as NBMPR-resistant uptake minus the non-mediated component, and the es-mediated uptake was estimated as the difference between the total uptake and that seen in the presence of NBMPR. Results are plotted as pmol of 2-chloro[ 3 H]adenosine accumulated/s per µl of cell water (V i ; ordinate) against the concentration of 2-chloro[ 3 H]adenosine used (abcissa). Each point is the mean + − S.E.M. from five experiments. The transporter kinetic constants derived from these data are shown in Table 3 .
Table 3 Effects of inhibiting CK2α activity on the uptake of 2-chloro[ 3 H]adenosine by GV7.21 cells
Cells were grown in the presence or absence of TET, as described in the text, and assessed for their capacity to accumulate 2-chloro[ 3 H]adenosine in the presence and absence of 50 nM NBMPR or 14 µM dipyridamole/NBMPR, as shown in Figure 4 . The substrate affinities (K m ) and maximum uptake rates (V max ) were derived from hyperbolic curves fitted to data plotted as shown in Figure 5 . The relative amount of ei-mediated uptake was also calculated for each experiment, and is given in parentheses. Each value represents the mean + − S.E.M. of five independent experiments. Significance of differences: *P < 0. There was a significant decrease (P < 0.05, paired t test, n = 6) in both hENT1 and hENT2 mRNAs within 4-12 h after induction of the catalytically dead CK2α , relative to the TET+ controls, but both transcripts had returned to control (TET+) levels by 16 h (Figure 8 ). 
DISCUSSION
The osteosarcoma cell variants used in the present study exhibited both NBMPR-sensitive (es) and NBMPR-insensitive (ei) equilibrative nucleoside transport activity. These uptake activities were probably mediated by transporters encoded by the genes hENT1 and hENT2 respectively (see Figure 7) . Using the binding of [ 3 H]NBMPR as a stoichiometric indicator of es transporters expressed at the plasma membrane [30] , it was apparent that these cells have a high density of es nucleoside transporters (∼ 100 000 per cell), typical of rapidly proliferating cells [3, 15, 33] (Figure 3) , indicating non-co-operative, one-site binding similar to that seen for this radioligand in many other systems. Furthermore, the affinity of the NBMPR binding site for a series of recognized nucleoside transport inhibitors (dilazep > draflazine > dipyridamole > soluflazine) was consistent with that found in previous studies on the es transporter in human cell lines [6, 29, 34] .
Induction of the catalytically inactive CK2α subunit in GV7.21 cells led to a 1.5-fold increase in the number of [ 3 H]NBMPR binding sites. In contrast, no change in binding was observed upon induction of the inactive CK2α subunit in GV13.35 cells (Table 2 ). These data infer that the α and α subunits of CK2 are differentially involved in the phosphorylation pathways that impact on the activity of es nucleoside transporters. Few functional differences have been found between the CK2 catalytic subunit isoforms. However, other studies involving the disruption of α /α subunit activities suggest that CK2α function is most important for maintaining optimal cell proliferation [35] .
Given that the number of es transporters (NBMPR binding sites) increased in response to a decrease in CK2α -mediated activity, it was expected that increasing CK2α activity (i.e. in RS2.31 cells) would produce a decrease in [ 3 H]NBMPR binding. However, this was not observed (Table 2) , probably because the RS2.31 cells already had sufficient CK2 activity for cellular regulation, such that inducing the expression of more CK2α was inconsequential. Nor was there any difference in either es-or ei-mediated uptake of Figure 6B ). It has been reported that cancer cell lines often have high levels of CK2 activity due to the important role of this enzyme in cell proliferation [12] , and hence functional nucleoside transporters may normally exist in a CK2-mediated phosphorylated state. The increase in es transporter density implied by these NBMPR binding data was corroborated by measuring the uptake of 2-chloro[
3 H]adenosine in the presence and absence of NBMPR or dipyridamole. This adenosine derivative has been described previously as an adenosine deaminase-resistant [36] high-affinity substrate for the es transporter in human erythrocytes [37] and fibroblast-like synoviocytes [38] . In the present study, it was observed that the maximum intracellular concentration of 2-chloro-[ 3 H]adenosine did not exceed the extracellular concentration, and that cellular ATP depletion had no effect on the initial rate or the maximum level of accumulation of 2-chloro[ 3 H]adenosine. These data suggest that 2-chloroadenosine was not phosphorylated by intracellular adenosine kinases, under the conditions of these Figure 8 Time course of the effect of CK2 inhibition on hENT1 and hENT2 mRNA levels GV7.21 cells were grown in either the presence (control) or absence (decreased CK2α activity) of TET for the indicated times (abscissa), and then harvested for RNA isolation. The amounts of hENT1 (A) and hENT2 (B) mRNAs, normalized to the β-actin signal, were determined as described for Figure 7 . Each bar is the mean + − S.E.M. of two amplification runs from each of three independent isolations. *P < 0.05 for significant difference between the TET+ and TET− conditions (Student's t test for paired data).
assays, making it a useful substrate for the kinetic analysis of equilibrative nucleoside transporter function. The V max for 2-chloro[ 3 H]adenosine uptake via the es transporter increased 1.8-fold upon induction of inactive CK2α , with no significant change in K m ( Table 3 ). The es-mediated uptake of [ 3 H]formycin B, a well established substrate for es and ei transporters, was also enhanced approx. 2-fold in GV7.21 cells upon induction of inactive CK2α ( Figure 6A ). These data correlated reasonably well with the 1.5-fold increase in [ 3 H]NBMPR binding seen upon induction of inactive CK2α in the GV7.21 cells, and suggest that the enhanced transport activity was due to an increase in the number of es transporters at the plasma membrane, as opposed to a change in substrate affinity. This appears to be a posttranscriptional effect of CK2α on the es transporter, possibly involving a decreased rate of transporter internalization in the absence of CK2-mediated phosphorylation, since there was not a corresponding increase in hENT1 mRNA observed over the 48 h analysis period ( Figure 8A ). In fact, there was a significant decrease in hENT1 mRNA levels observed within 4 h after TET wash-out that had returned to control levels by 16 h. This transient inhibition of hENT1 transcription might have contributed to the slight decrease in [ 3 H]NBMPR binding observed at the 4 h time point (see Figure 2B) . Therefore, inhibition of CK2α activity appears to have a dual effect on ENT1/es activity: a delayed posttranslational increase in the number of es transporters functioning at the plasma membrane, overlaid with a transient inhibition of ENT1 transcription. The attenuated increase in [ 3 H]NBMPR binding observed at the 8 and 12 h time points, relative to the later time points (see Figure 2B ), may be a consequence of these overlapping effects of CK2α inhibition.
Approx. 40 % of the equilibrative uptake of 2-chloro[ 3 H]-adenosine by the osteosarcoma cells was mediated by the ei subtype of nucleoside transporter. This is similar to the ratio of NBMPR-sensitive to -insensitive [ 3 H]formycin B uptake by these cells (see Figure 6) , which further supports the use of 2-chloro-[
3 H]adenosine as a substrate for the equilibrative transporters. This is the first study to show that 2-chloro[ 3 H]adenosine is a substrate for the ei system, with a K m (29 + − 3 µM) comparable with that seen for the es transporter (27 + − 9 µM). These K m values are similar to that reported previously for 2-chloro[
3 H]adenosine uptake by the es transporter of human erythrocytes [37] . Inhibition of CK2 activity by induction of the inactive CK2α subunit in GV7.21 cells for 48 h decreased significantly the V max of ei-mediated 2-chloro[ 3 H]adenosine uptake. There was also a significant decrease in mENT2 mRNA levels within 4 h of induction of the inactive CK2α ( Figure 8B ). However, the ENT2 mRNA level in the TET− cells had returned to control levels by 12 h, and was maintained at this level for up to 48 h (the time at which the cells were harvested for the functional uptake studies). It is, nevertheless, possible that this early transient inhibition of hENT2 transcription led to the subsequent reduction of ei transport activity observed. The overall effect of changing the relative contributions of es and ei transporters on the cell nucleoside balance is unknown, but ei is able to transport nucleobases such as hypoxanthine, in addition to nucleosides [39] , and has a lower affinity for cytidine and guanosine than does the es system [40, 41] . This is the first report describing the modification of nucleoside transport activity by CK2 manipulation. However, other protein kinases, such as protein kinase A and protein kinase C, have been shown to exert at least indirect effects on nucleoside transport activity [17] [18] [19] [20] . While there was a transient transcriptional effect of CK2α inhibition on es function, the timing and direction of this transcriptional change did not correlate with the changes in es activity. Thus the predominant effect of CK2α on es appears to be post-translational. The simplest interpretation of these data is that phosphorylation of the es transporter by CK2α leads to internalization, and thereby functional deactivation, of the transporter. It is also possible that CK2 might phosphorylate other cellular proteins which could then phosphorylate or interact with the es transporter to modify function or membrane localization. For example, there is recent evidence that nucleoside transport activity is sensitive to changes in the MAP kinase (mitogen-activated protein kinase) pathway [42] , and CK2 has been reported to interact with both protein phosphatase 2A [43] and MAP kinase phosphatase 3 [44] , and thereby modify MAP kinase signalling cascades. In addition, ENT1 activity in macrophages can be repressed post-transcriptionally by interferon-γ via a STAT1 (signal transduction and activators of transcription 1)-dependent mechanism [45] . It is known that interferon-γ can also stimulate CK2 activity [46] , and it is thus possible that CK2 might be involved in the aforementioned STAT1-dependent inhibition of ENT1.
NBMPR-sensitive (es-like) nucleoside transport proteins have been shown to exist in intracellular compartments of mammalian cells [47] [48] [49] [50] . As seen for glucose transporters [51] , there is likely to be an intracellular pool of nucleoside transporters that is in dynamic equilibrium with those in the plasma membrane. The data obtained from the present study suggest that the lifetime of es transport proteins in the plasma membrane and/or their trafficking between subcellular membrane compartments is regulated, in part, by CK2-mediated phosphorylation.
